X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Owl Therapeutics will advance Abliva's clinical development of NeuroSTAT (OWL-1410) with orphan drug designation, which is under development for the prevention and treatment of moderate to severe traumatic brain injury (TBI).
Lead Product(s): OWL-1410
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NeuroSTAT
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Owl Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 17, 2023
Details:
KL1333 is a potent modulator of the cellular levels of NAD, a central co-enzyme in the cell’s energy metabolism. The clinical KL1333 development plan will target patients with genetically confirmed MIDD-MELAS or KSS-CPEO spectrum disorders with multi-organ systemic symptoms.
Lead Product(s): KL1333
Therapeutic Area: Genetic Disease Product Name: KL1333
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
